Example: Heart Attack

Clinical Trials on Leukemia, Lymphocytic, Chronic, B-Cell

Total 1832 results

NCT04204057

Completed

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT01373229

Completed

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT03720561

Active, not recruiting

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT02869529

Recruiting

Institut Paoli Calmettes Chronic Lymphatic Leukemia Database

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT03265717

Terminated

DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT00923182

Completed

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT02912754

Unknown status

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT03343678

Withdrawn

This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT03462719

Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT01456182

Withdrawn

Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT01296932

Completed

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT00206726

Completed

Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT02406742

Completed

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT00951457

Completed

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT00545714

Completed

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT02757586

Unknown status

Treatment of Chronic Lymphocytic Leukemia

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT00220311

Completed

A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT02759016

Completed

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT03331198

Recruiting

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
NCT02666898

Completed

Phase II Trial GA101 Inbrutinib B CLL

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT04028531

Recruiting

Understanding Chronic Lymphocytic Leukemia

Conditions: Chronic Lymphocytic Leukemia
NCT01028430

Recruiting

B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging

Conditions: Chronic Lymphocytic Leukemia
NCT00738829

Completed

Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
NCT01005979

Terminated

A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
NCT01982175

Unknown status

Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia

Conditions: B-cell Chronic Lymphocytic Leukemia